Agilent Technologies, Inc. (A) EV/EBIT Ratio: 25.74x
Is Agilent Technologies, Inc.’s EV/EBIT ratio high or low?
Agilent Technologies, Inc.'s EV/EBIT ratio of 25.74x is 11% below its 5-year average of 28.93x, near the low end of its 5-year range (20.54x–48.74x).
The EV/EBIT ratio for Agilent Technologies, Inc. (A) is 25.74x as of Wednesday, June 10, 2026. It is below its 12-month average by 1.97% (26.26x).
A EV/EBIT Ratio Chart
A Average EV/EBIT Ratio Chart
A Current vs Average EV/EBIT Ratio Chart
A EV/EBIT Ratio Metrics
EV/EBIT RATIO
25.74x
EV/EBIT RATIO AVG TTM
26.26x
EV/EBIT RATIO AVG 3Y
27.11x
EV/EBIT RATIO AVG 5Y
28.93x
EV/EBIT RATIO AVG 10Y
29.02x
EV/EBIT RATIO AVG 15Y
24.97x
EV/EBIT RATIO AVG 20Y
26.14x
CURRENT VS TTM AVG
-1.97%
CURRENT VS 3Y AVG
-5.07%
CURRENT VS 5Y AVG
-11.03%
CURRENT VS 10Y AVG
-11.31%
CURRENT VS 15Y AVG
+3.09%
CURRENT VS 20Y AVG
-1.53%
A Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | — | 25.74x | 26.26x | 27.11x | 28.93x |
| Zoetis Inc. (ZTS) | $34.20B | 11.68x | 17.91x | 24.03x | 27.39x |
| Humana Inc. (HUM) | $43.60B | 38.19x | 22.06x | 19.17x | 18.78x |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 32.96x | 39.77x | 38.49x | 42.83x |
| Centene Corporation (CNC) | $31.94B | N/A | 10.37x | 16.91x | 20.65x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 13.56x | 20.40x | 24.04x | 30.04x |
| DexCom, Inc. (DXCM) | $29.24B | 29.06x | 38.74x | 65.30x | 101.94x |
| Biogen Inc. (BIIB) | $29.00B | 20.98x | 13.26x | 14.80x | 15.73x |
| Veeva Systems Inc. (VEEV) | $27.37B | 27.25x | 45.67x | 60.73x | 66.40x |
| Waters Corporation (WAT) | $23.83B | 54.60x | 27.55x | 26.51x | 26.24x |
Agilent Technologies, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The EV/EBIT ratio for A stock is 25.74x.
- Is Agilent Technologies, Inc.'s EV/EBIT ratio high or low?
- Agilent Technologies, Inc.'s EV/EBIT ratio of 25.74x is 11% below its 5-year average of 28.93x, near the low end of its 5-year range (20.54x–48.74x).
- What is the TTM average EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The TTM average EV/EBIT ratio for A stock is 26.26x.
- What is the 3Y average EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The 3Y average EV/EBIT ratio for A stock is 27.11x.
- What is the 5Y average EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The 5Y average EV/EBIT ratio for A stock is 28.93x.
- What is the 10Y average EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The 10Y average EV/EBIT ratio for A stock is 29.02x.
- What is the 15Y average EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The 15Y average EV/EBIT ratio for A stock is 24.97x.
- What is the 20Y average EV/EBIT ratio for Agilent Technologies, Inc. (A)?
- The 20Y average EV/EBIT ratio for A stock is 26.14x.
Agilent Technologies, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-09 | 25.74x |
| 2026-06-08 | 25.23x |
| 2026-06-05 | 25.73x |
| 2026-06-04 | 26.27x |
| 2026-06-03 | 26.09x |
| 2026-06-02 | 25.66x |
| 2026-06-01 | 25.83x |
| 2026-05-29 | 27.53x |
| 2026-05-28 | 27.50x |
| 2026-05-27 | 23.69x |
| 2026-05-26 | 23.54x |
| 2026-05-22 | 23.52x |
| 2026-05-21 | 23.49x |
| 2026-05-20 | 23.29x |
| 2026-05-19 | 22.66x |
| 2026-05-18 | 22.96x |
| 2026-05-15 | 22.88x |
| 2026-05-14 | 23.19x |
| 2026-05-13 | 23.09x |
| 2026-05-12 | 23.12x |
| 2026-05-11 | 22.84x |
| 2026-05-08 | 23.65x |
| 2026-05-07 | 24.24x |
| 2026-05-06 | 24.05x |
| 2026-05-05 | 24.02x |
| 2026-05-04 | 22.98x |
| 2026-05-01 | 23.43x |
| 2026-04-30 | 23.63x |
| 2026-04-29 | 22.81x |
| 2026-04-28 | 23.50x |
| 2026-04-27 | 23.65x |
| 2026-04-24 | 23.63x |
| 2026-04-23 | 23.41x |
| 2026-04-22 | 24.59x |
| 2026-04-21 | 24.91x |
| 2026-04-20 | 24.69x |
| 2026-04-17 | 24.87x |
| 2026-04-16 | 24.16x |
| 2026-04-15 | 24.46x |
| 2026-04-14 | 24.58x |
| 2026-04-13 | 24.02x |
| 2026-04-10 | 23.54x |
| 2026-04-09 | 23.60x |
| 2026-04-08 | 23.90x |
| 2026-04-07 | 23.31x |
| 2026-04-06 | 23.50x |
| 2026-04-02 | 23.62x |
| 2026-04-01 | 23.44x |
| 2026-03-31 | 23.33x |
| 2026-03-30 | 22.94x |
| 2026-03-27 | 22.60x |
| 2026-03-26 | 23.23x |
| 2026-03-25 | 23.13x |
| 2026-03-24 | 23.37x |
| 2026-03-23 | 22.95x |
| 2026-03-20 | 22.81x |
| 2026-03-19 | 22.89x |
| 2026-03-18 | 22.84x |
| 2026-03-17 | 23.09x |
| 2026-03-16 | 22.91x |
| 2026-03-13 | 22.85x |
| 2026-03-12 | 22.87x |
| 2026-03-11 | 23.61x |
| 2026-03-10 | 23.61x |
| 2026-03-09 | 23.85x |
| 2026-03-06 | 23.54x |
| 2026-03-05 | 24.13x |
| 2026-03-04 | 24.61x |
| 2026-03-03 | 24.32x |
| 2026-03-02 | 23.75x |
| 2026-02-27 | 24.37x |
| 2026-02-26 | 24.29x |
| 2026-02-25 | 25.01x |
| 2026-02-24 | 24.95x |
| 2026-02-23 | 24.91x |
| 2026-02-20 | 24.66x |
| 2026-02-19 | 25.32x |
| 2026-02-18 | 25.43x |
| 2026-02-17 | 24.84x |
| 2026-02-13 | 25.22x |
| 2026-02-12 | 25.04x |
| 2026-02-11 | 25.81x |
| 2026-02-10 | 25.83x |
| 2026-02-09 | 25.54x |
| 2026-02-06 | 25.94x |
| 2026-02-05 | 25.95x |
| 2026-02-04 | 26.59x |
| 2026-02-03 | 26.43x |
| 2026-02-02 | 27.06x |
| 2026-01-30 | 26.76x |
| 2026-01-29 | 26.65x |
| 2026-01-28 | 26.76x |
| 2026-01-27 | 27.16x |
| 2026-01-26 | 27.11x |
| 2026-01-23 | 26.99x |
| 2026-01-22 | 27.68x |
| 2026-01-21 | 27.90x |
| 2026-01-20 | 27.14x |
| 2026-01-16 | 27.87x |
| 2026-01-15 | 28.87x |
| 2026-01-14 | 29.08x |
| 2026-01-13 | 29.15x |
| 2026-01-12 | 29.48x |
| 2026-01-09 | 29.58x |
| 2026-01-08 | 29.05x |
| 2026-01-07 | 29.44x |
| 2026-01-06 | 29.40x |
| 2026-01-05 | 28.50x |
| 2026-01-02 | 27.55x |
| 2025-12-31 | 27.19x |
| 2025-12-30 | 27.48x |
| 2025-12-29 | 27.54x |
| 2025-12-26 | 27.63x |
| 2025-12-24 | 27.62x |
| 2025-12-23 | 27.63x |
| 2025-12-22 | 27.66x |
| 2025-12-19 | 27.41x |
| 2025-12-18 | 28.32x |
| 2025-12-17 | 28.27x |
| 2025-12-16 | 28.77x |
| 2025-12-15 | 29.05x |
| 2025-12-12 | 28.87x |
| 2025-12-11 | 29.50x |
| 2025-12-10 | 29.61x |
| 2025-12-09 | 29.06x |
| 2025-12-08 | 29.41x |
| 2025-12-05 | 30.01x |
| 2025-12-04 | 30.57x |
| 2025-12-03 | 30.76x |
| 2025-12-02 | 30.67x |
| 2025-12-01 | 30.92x |
| 2025-11-28 | 31.59x |
| 2025-11-26 | 31.77x |
| 2025-11-25 | 32.32x |
| 2025-11-24 | 31.61x |
| 2025-11-21 | 31.15x |
| 2025-11-20 | 29.93x |
| 2025-11-19 | 29.80x |
| 2025-11-18 | 29.69x |
| 2025-11-17 | 29.82x |
| 2025-11-14 | 30.28x |
| 2025-11-13 | 30.29x |
| 2025-11-12 | 31.20x |
| 2025-11-11 | 30.79x |
| 2025-11-10 | 30.18x |
| 2025-11-07 | 30.26x |
| 2025-11-06 | 30.41x |
| 2025-11-05 | 30.27x |
| 2025-11-04 | 30.13x |
| 2025-11-03 | 29.86x |
| 2025-10-31 | 30.18x |
| 2025-10-30 | 29.59x |
| 2025-10-29 | 29.56x |
| 2025-10-28 | 30.08x |
| 2025-10-27 | 30.23x |
| 2025-10-24 | 30.51x |
| 2025-10-23 | 30.40x |
| 2025-10-22 | 30.09x |
| 2025-10-21 | 30.05x |
| 2025-10-20 | 29.52x |
| 2025-10-17 | 29.31x |
| 2025-10-16 | 29.15x |
| 2025-10-15 | 28.86x |
| 2025-10-14 | 28.54x |
| 2025-10-13 | 28.58x |
| 2025-10-10 | 28.26x |
| 2025-10-09 | 28.95x |
| 2025-10-08 | 29.09x |
| 2025-10-07 | 28.65x |
| 2025-10-06 | 29.25x |
| 2025-10-03 | 29.25x |
| 2025-10-02 | 28.67x |
| 2025-10-01 | 28.65x |
| 2025-09-30 | 26.63x |
| 2025-09-29 | 25.72x |
| 2025-09-26 | 25.65x |
| 2025-09-25 | 25.36x |
| 2025-09-24 | 25.85x |
| 2025-09-23 | 26.15x |
| 2025-09-22 | 26.23x |
| 2025-09-19 | 26.23x |
| 2025-09-18 | 26.49x |
| 2025-09-17 | 26.31x |
| 2025-09-16 | 26.40x |
| 2025-09-15 | 26.09x |
| 2025-09-12 | 25.62x |
| 2025-09-11 | 26.31x |
| 2025-09-10 | 25.80x |
| 2025-09-09 | 26.22x |
| 2025-09-08 | 26.59x |
| 2025-09-05 | 26.71x |
| 2025-09-04 | 26.66x |
| 2025-09-03 | 26.01x |
| 2025-09-02 | 26.01x |
| 2025-08-29 | 26.10x |
| 2025-08-28 | 26.55x |
| 2025-08-27 | 25.29x |
| 2025-08-26 | 25.21x |
| 2025-08-25 | 25.38x |
| 2025-08-22 | 25.88x |
| 2025-08-21 | 24.98x |
| 2025-08-20 | 25.37x |
| 2025-08-19 | 25.58x |
| 2025-08-18 | 25.18x |
| 2025-08-15 | 25.39x |
| 2025-08-14 | 25.33x |
| 2025-08-13 | 25.61x |
| 2025-08-12 | 25.01x |
| 2025-08-11 | 24.37x |
| 2025-08-08 | 24.47x |
| 2025-08-07 | 24.34x |
| 2025-08-06 | 24.19x |
| 2025-08-05 | 24.53x |
| 2025-08-04 | 24.52x |
| 2025-08-01 | 24.25x |
| 2025-07-31 | 24.51x |
| 2025-07-30 | 25.16x |
| 2025-07-29 | 25.52x |
| 2025-07-28 | 25.46x |
| 2025-07-25 | 25.59x |
| 2025-07-24 | 25.62x |
| 2025-07-23 | 25.45x |
| 2025-07-22 | 24.79x |
| 2025-07-21 | 23.95x |
| 2025-07-18 | 24.34x |
| 2025-07-17 | 24.82x |
| 2025-07-16 | 24.23x |
| 2025-07-15 | 24.13x |
| 2025-07-14 | 25.57x |
| 2025-07-11 | 26.21x |
| 2025-07-10 | 26.39x |
| 2025-07-09 | 25.81x |
| 2025-07-08 | 25.76x |
| 2025-07-07 | 25.40x |
| 2025-07-03 | 25.83x |
| 2025-07-02 | 25.69x |
| 2025-07-01 | 25.64x |
| 2025-06-30 | 25.15x |
| 2025-06-27 | 25.39x |
| 2025-06-26 | 25.44x |
| 2025-06-25 | 25.28x |
| 2025-06-24 | 25.08x |
| 2025-06-23 | 24.77x |
| 2025-06-20 | 24.66x |
| 2025-06-18 | 24.65x |
| 2025-06-17 | 24.77x |
| 2025-06-16 | 25.36x |
| 2025-06-13 | 24.97x |
| 2025-06-12 | 25.33x |
| 2025-06-11 | 25.50x |
| 2025-06-10 | 25.66x |
| 2025-06-09 | 24.90x |
| 2025-06-06 | 24.71x |
| 2025-06-05 | 24.33x |
| 2025-06-04 | 24.54x |
| 2025-06-03 | 24.10x |
| 2025-06-02 | 23.75x |
| 2025-05-30 | 23.93x |
| 2025-05-29 | 23.25x |
| 2025-05-28 | 22.78x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell